Barinthus Biotherapeutics plc
BRNS
$1.20
$0.0151.27%
NASDAQ
06/30/2025 | 03/31/2025 | ||||
---|---|---|---|---|---|
Revenue | -- | -- | |||
Total Other Revenue | -- | -- | |||
Total Revenue | -- | -- | |||
Cost of Revenue | -100.01% | 11,428.99% | |||
Gross Profit | 100.01% | -11,428.99% | |||
SG&A Expenses | 18.58% | 484.87% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | 55.17% | 84.24% | |||
Total Operating Expenses | 6.72% | 672.33% | |||
Operating Income | -6.72% | -672.33% | |||
Income Before Tax | -7.47% | 4.41% | |||
Income Tax Expenses | -13.64% | -833.33% | |||
Earnings from Continuing Operations | -7.47% | 4.53% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -80.00% | -80.39% | |||
Net Income | -7.51% | 4.34% | |||
EBIT | -6.72% | -672.33% | |||
EBITDA | -7.32% | -849.68% | |||
EPS Basic | -7.30% | 4.59% | |||
Normalized Basic EPS | -5.71% | -964.95% | |||
EPS Diluted | -6.86% | 4.20% | |||
Normalized Diluted EPS | -5.71% | -964.95% | |||
Average Basic Shares Outstanding | 0.19% | 0.27% | |||
Average Diluted Shares Outstanding | 0.19% | 0.27% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |